#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV treatment

Here are some of the most compelling HIV updates from the annual Conference on Retroviruses and Opportunistic Infections in San Francisco: Merck details Phase 3 wins for two-drug regimen Merck